» Articles » PMID: 35508223

Tissue Engineered Drug Delivery Vehicles: Methods to Monitor and Regulate the Release Behavior

Overview
Specialty Pharmacology
Date 2022 May 4
PMID 35508223
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue engineering is a rapidly evolving, multidisciplinary field that aims at generating or regenerating 3D functional tissues for in vitro disease modeling and drug screening applications or for in vivo therapies. A variety of advanced biological and engineering methods are increasingly being used to further enhance and customize the functionality of tissue engineered scaffolds. To this end, tunable drug delivery and release mechanisms are incorporated into tissue engineering modalities to promote different therapeutic processes, thus, addressing challenges faced in the clinical applications. In this review, we elaborate the mechanisms and recent developments in different drug delivery vehicles, including the quantum dots, nano/micro particles, and molecular agents. Different loading strategies to incorporate the therapeutic reagents into the scaffolding structures are explored. Further, we discuss the main mechanisms to tune and monitor/quantify the release kinetics of embedded drugs from engineered scaffolds. We also survey the current trend of drug delivery using stimuli driven biopolymer scaffolds to enable precise spatiotemporal control of the release behavior. Recent advancements, challenges facing current scaffold-based drug delivery approaches, and areas of future research are discussed.

Citing Articles

Therapeutic Controlled Release Strategies for Human Osteoarthritis.

Wang D, Liu W, Venkatesan J, Madry H, Cucchiarini M Adv Healthc Mater. 2024; 14(2):e2402737.

PMID: 39506433 PMC: 11730424. DOI: 10.1002/adhm.202402737.


Current advances in the development of microRNA-integrated tissue engineering strategies: a cornerstone of regenerative medicine.

Castanon-Cortes L, Bravo-Vazquez L, Santoyo-Valencia G, Medina-Feria S, Sahare P, Duttaroy A Front Bioeng Biotechnol. 2024; 12:1484151.

PMID: 39479296 PMC: 11521876. DOI: 10.3389/fbioe.2024.1484151.


Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium.

Cong X, Zhang Z, Li H, Yang Y, Zhang Y, Sun T J Nanobiotechnology. 2024; 22(1):620.

PMID: 39396002 PMC: 11470712. DOI: 10.1186/s12951-024-02892-9.


Supramolecular Nano-Tracker for Real-Time Tracking of Drug Release and Efficient Combination Therapy.

Chen X, Chen F, Lu Y, Li Q, Li S, Zheng C Adv Sci (Weinh). 2024; 11(36):e2404731.

PMID: 39072943 PMC: 11423228. DOI: 10.1002/advs.202404731.


Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies.

Blanco E, Silva-Pilipich N, Bocanegra A, Chocarro L, Procopio A, Ausin K Br J Cancer. 2024; 130(5):869-879.

PMID: 38195888 PMC: 10912768. DOI: 10.1038/s41416-023-02561-y.